학술논문
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
Document Type
article
Author
Frank Jacobsen; Juliane Kraft; Cornelia Schroeder; Claudia Hube-Magg; Martina Kluth; Dagmar S. Lang; Ronald Simon; Guido Sauter; Jakob R. Izbicki; Till S. Clauditz; Andreas M. Luebke; Andrea Hinsch; Waldemar Wilczak; Corinna Wittmer; Franziska Büscheck; Doris Höflmayer; Sarah Minner; Maria Christina Tsourlakis; Hartwig Huland; Markus Graefen; Lars Budäus; Imke Thederan; Georg Salomon; Thorsten Schlomm; Nathaniel Melling
Source
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 9, Pp 707-715 (2017)
Subject
Language
English
ISSN
1476-5586
1522-8002
1522-8002
Abstract
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P